Neurocrine Biosciences to Present at Stifel 3rd Annual CNS Day

Rhea-AI Summary

Neurocrine Biosciences (Nasdaq: NBIX) will present at the Stifel 3rd Annual CNS Day on April 1, 2021, at 12:30 p.m. ET. The presentation will feature Eiry Roberts and Kyle Gano, focusing on the company’s advancements in neuroscience treatments. Investors can access the live webcast on the company's website, with a replay available approximately one hour after the event. Neurocrine is dedicated to developing treatments for neurological, endocrine, and psychiatric disorders, and has a robust portfolio that includes FDA-approved therapies for various conditions.

News Market Reaction – NBIX

+1.65%

+1.65% Session move

In the trading session that priced this news, NBIX gained 1.65%, reflecting a mild positive market reaction.

Data tracked by StockTitan Argus on the day of publication.

AI-generated analysis. How Rhea-AI works. Not financial advice.

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

SAN DIEGO, March 25, 2021 /PRNewswire/ -- Neurocrine Biosciences, Inc. (Nasdaq: NBIX) will present at the Stifel 3^rd Annual CNS Day at 12:30 p.m. Eastern Time on Thursday Apr. 1, 2021. Eiry Roberts, Chief Medical Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will present at the conference.

The live presentation will be webcast and may be accessed on the Company's website under Investors at www.neurocrine.com. A replay of the presentation will be available on the website approximately one hour after the conclusion of the events and will be archived for approximately one month.

About Neurocrine Biosciences
Neurocrine Biosciences is a neuroscience-focused, biopharmaceutical company dedicated to discovering, developing and delivering life-changing treatments for people with serious, challenging and under-addressed neurological, endocrine and psychiatric disorders. The company's diverse portfolio includes FDA-approved treatments for tardive dyskinesia, Parkinson's disease, endometriosis*, uterine fibroids* and clinical programs in multiple therapeutic areas. For nearly three decades, Neurocrine Biosciences has specialized in targeting and interrupting disease-causing mechanisms involving the interconnected pathways of the nervous and endocrine systems. For more information, visit neurocrine.com, and follow the company on LinkedIn. (*in collaboration with AbbVie)

 

View original content to download multimedia:http://www.prnewswire.com/news-releases/neurocrine-biosciences-to-present-at-stifel-3rd-annual-cns-day-301256161.html

SOURCE Neurocrine Biosciences, Inc.

FAQ

When will Neurocrine Biosciences present at the Stifel 3rd Annual CNS Day?

Neurocrine Biosciences will present on April 1, 2021, at 12:30 p.m. ET.

Who will represent Neurocrine Biosciences at the CNS Day event?

Eiry Roberts, Chief Medical Officer, and Kyle Gano, Chief Business Development and Strategy Officer, will represent Neurocrine Biosciences.

How can I access the Neurocrine Biosciences presentation?

The presentation can be accessed via a live webcast on the company's website.

Will there be a replay of the Neurocrine Biosciences presentation?

Yes, a replay will be available on the website approximately one hour after the presentation concludes.

What is the focus of Neurocrine Biosciences?

Neurocrine Biosciences focuses on developing treatments for neurological, endocrine, and psychiatric disorders.